Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship for...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodier, Thomas, Puszkiel, Alicja, Cardoso, Evelina, Balakirouchenane, David, Narjoz, Céline, Arrondeau, Jennifer, Fallet, Vincent, Khoudour, Nihel, Guidi, Monia, Vidal, Michel, Declèves, Xavier, Csajka, Chantal, Alexandre, Jérôme, Cadranel, Jacques, Fabre, Elizabeth, Wislez, Marie, Goldwasser, François, Blanchet, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504753/
https://www.ncbi.nlm.nih.gov/pubmed/36145591
http://dx.doi.org/10.3390/pharmaceutics14091844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504753/
https://www.ncbi.nlm.nih.gov/pubmed/36145591
http://dx.doi.org/10.3390/pharmaceutics14091844

Ejemplares similares